Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH - Free Report) TSE: AUP in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 454,259 shares of the biotechnology company's stock, valued at approximately $3,330,000. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.32% of Aurinia Pharmaceuticals as of its most recent SEC filing.
Several other hedge funds and other institutional investors have also recently modified their holdings of AUPH. SG Americas Securities LLC grew its holdings in shares of Aurinia Pharmaceuticals by 4,307.9% during the third quarter. SG Americas Securities LLC now owns 547,727 shares of the biotechnology company's stock worth $4,015,000 after purchasing an additional 535,301 shares in the last quarter. Stonepine Capital Management LLC bought a new position in Aurinia Pharmaceuticals in the second quarter valued at $1,713,000. AQR Capital Management LLC purchased a new stake in Aurinia Pharmaceuticals during the second quarter valued at about $1,155,000. Algert Global LLC lifted its stake in Aurinia Pharmaceuticals by 106.8% during the second quarter. Algert Global LLC now owns 193,804 shares of the biotechnology company's stock worth $1,107,000 after purchasing an additional 100,104 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Aurinia Pharmaceuticals by 18.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 488,721 shares of the biotechnology company's stock valued at $2,791,000 after purchasing an additional 77,510 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In other news, Director Jeffrey Allen Bailey sold 4,557 shares of Aurinia Pharmaceuticals stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $8.43, for a total value of $38,415.51. Following the completion of the sale, the director now directly owns 13,356 shares in the company, valued at $112,591.08. The trade was a 25.44 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 4.30% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of research analysts have commented on AUPH shares. HC Wainwright reiterated a "buy" rating and set a $13.00 price target on shares of Aurinia Pharmaceuticals in a research report on Friday, September 6th. StockNews.com upgraded Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Friday, November 8th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $10.00 target price on shares of Aurinia Pharmaceuticals in a research note on Monday, September 16th. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of $10.00.
Get Our Latest Analysis on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Stock Down 1.7 %
NASDAQ AUPH traded down $0.15 during trading hours on Monday, reaching $8.71. 1,620,451 shares of the company's stock traded hands, compared to its average volume of 1,607,627. The firm has a market cap of $1.25 billion, a PE ratio of -59.06 and a beta of 1.45. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.71 and a 52-week high of $9.74. The firm has a 50-day simple moving average of $7.43 and a 200 day simple moving average of $6.36.
About Aurinia Pharmaceuticals
(
Free Report)
Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Articles
Before you consider Aurinia Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aurinia Pharmaceuticals wasn't on the list.
While Aurinia Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
